ROCKVILLE, Md., June 13 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA - News), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced that Phase II data for its sleep disorder compound VEC-162 will be presented at the SLEEP 2006 20th Anniversary Meeting of the Associated Professional Sleep Societies at the Salt Palace Convention Center in Salt Lake City on June 22nd.
